Abstract
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.
Methods A multicentre, single-arm, hypothesis-driven phase 2 trial was planned to study the effect of Tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints). A cohort of patients consecutively enrolled after phase 2 was used as a validation dataset. A multivariable logistic regression was performed to generate hypotheses, while controlling for possible confounders.
Results out of 301 patients in phase 2 intention-to-treat (ITT) analysis, 180 (59.8%) received tocilizumab. With 67 death events, lethality rates were 18.4% (97.5%CI: 13.6-24.0, P=0.52) and 22.4% (97.5%CI: 17.2-28.3, P<0.001) at 14 and 30 days. Lethality rates were lower in the validation dataset, including 920 patients. No signal of specific drug toxicity was reported. The multivariable logistic regression suggests tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline. Also, it supports a positive effect on lethality rate of the use of corticosteroids.
Conclusions Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Such result support the use of tocilizumab while waiting for ongoing phase 3 trials.
Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)
Competing Interest Statement
Dr. Perrone reports grants, personal fees and non-financial support from Bayer; grants and personal fees from Incyte, Astra Zeneca, Pierre Fabre; personal fees from Celgene, Janssen Cilag, Roche, Pfizer, Sandoz, outside the submitted work. Dr. Piccirillo reports grants and personal fees from AstraZeneca; grants from Roche; personal fees from Daichii Sankyo, GSK, MSD; non-financial support from Bayer, outside the submitted work. Dr. Ascierto reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees and other from MSD; personal fees from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, outside the submitted work. Dr. Salvarani reports grants and personal fees from Roche; personal fees from Sanofi-Genzyme, Abbvie, Pfizer, Eli-Lilly, Novartis, outside the submitted work. Dr. Castelli reports grants from Gilead, ViiV, GSK, Janssen, Eiger, Roche, Gilead, outside the submitted work. Dr. Gravina reports non-financial support from Pfizer, outside the submitted work. Dr. Lichtner reports grants from Gilead; personal fees from Abbvie, Merck, Janseen, Angelini, outside the submitted work.
Clinical Trial
NCT04317092
Clinical Protocols
http://www.repo.epiprev.it/1604
http://www.repo.epiprev.it/1610
Funding Statement
No specific funding was available for this study. Tocilizumab was provided by the pharmaceutical company (Roche) free of charge. The National Cancer Institute of Naples was the sponsor of the study and had full property of data and full access to them and final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
According to a specific Italian law, TOCIVID-19 was approved for all Italian centers by the National Ethical Committee at the Lazzaro Spallanzani Institute on March 18th, 2020; two amendments followed on March 24th, 2020 and April 28th, 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available in the near future.
